Image

Global Antiplatelet Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2020
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Antiplatelet Drugs Market, By Drug (Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Others), Indication (Myocardial Infraction, Percutaneous Coronary Interventions, Arterial Thrombosis, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

 

Antiplatelet Drugs Market

Market Analysis and Size

In recent years, the antiplatelet drugs market is anticipated to grow rapidly during the forecast period. Antiplatelet medications, which are sometimes incorrectly referred to as "blood thinners," help to prevent blood clots. These medications work by preventing hazardous blood clots from sticking together. According to the worldwide antiplatelet pharmaceuticals market, antiplatelet medications are also used to treat patients undergoing difficult surgical operations such as angioplasty. Globally, an ageing population and fast changing lifestyles are contributing to an increase in the prevalence of cardiac disease. World Health Organization (WHO) estimates that 15 million people die each year from heart conditions such as heart strokes. These factors are projected to influence the growth of the worldwide antiplatelet drugs market in the future years.

Data Bridge Market Research analyses that the antiplatelet drugs market was valued at USD 2.05 billion in 2021 and is expected to reach USD 3.82 billion by 2029, registering a CAGR of 8.10% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Antiplatelet medicines, also known as platelet agglutination inhibitors, are a class of pharmaceuticals that serve to reduce or prevent blood clotting by restricting platelet activity to stick or bind together. Clotting of blood is a physiological response of the body that aids in controlling external bleeding during injury. When blood clots form within blood vessels, they can cause serious complications because they restrict blood flow. As a result, antiplatelet medications are used therapeutically to stop clotting as quickly as feasible.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drug (Aspirin, Clopidogrel, Ticagrelor, Prasugrel,  Others), Indication (Myocardial Infraction, Percutaneous Coronary Interventions, Arterial Thrombosis, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Bausch Health Companies Inc. (Canada), Bayer AG (Germany), AstraZeneca (UK), Johnson & Johnson Private Limited (US),  Boehringer Ingelheim International GmbH. (Germany), Bristol-Myers Squibb Company (US), Merck & Co., Inc. (US), DAIICHI SANKYO COMPANY, LIMITED (Japan), Otsuka America Pharmaceutical, Inc. (US), Eli Lilly and Company (US), AbbVie Inc. (US), Genentech, Inc., Baxter (US)

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Antiplatelet Drugs Market Dynamics

Drivers

  • Rise in the incidences of cardiovascular diseases

The rising incidences of cardiovascular diseases is a major factor driving the antiplatelet drugs market's growth rate. In both developed and developing economies, cardiovascular illnesses are the leading cause of death. According to the Centers for Disease Control and Prevention (CDC), over 800,000 individuals in the United States die each year from stroke and other cardiovascular disorders.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of antiplatelet drugs market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness myriad fungal infections will expand the antiplatelet drugs market. Additionally, high disposable income and sedentary lifestyle of people will result in the expansion of the antiplatelet drugs market. Along with this, rising geriatric population and surge in thrombotic events will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the antiplatelet drugs market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the antiplatelet drugs market during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the antiplatelet drugs will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and limitations in safety, efficacy and tolerability of some antiplatelet drugs will challenge the antiplatelet drugs market. Additionally, the availability of counterfeit drugs and side effects linked with antiplatelet drugs will restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This antiplatelet drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antiplatelet drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Antiplatelet drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Antiplatelet Drugs Market

Over the projected period, the antiplatelet drugs market is expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations have imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world are having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the antiplatelet drugs market.

Recent Development

  • In June 2021, Alfasigma announced the approval of the European license for bentracimab from PhaseBio. Bentracimab is a novel human monoclonal antibody fragment that has been shown to reverse the antiplatelet effects of Brilinta / Brilique in previous clinical tests.

Global Antiplatelet Drugs Market Scope

The antiplatelet drugs market is segmented on the basis of drug, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug

  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Prasugrel
  • Others

On the basis of drug, the global antiplatelet drugs market is segmented into aspirin, clopidogrel, ticagrelor, prasugrel and others.

Indication

  • Myocardial Infraction
  • Percutaneous Coronary Interventions
  • Arterial Thrombosis
  • Others

Based on indication, the global antiplatelet drugs market is segmented into myocardial infraction, percutaneous coronary interventions, arterial thrombosis and others.

Route of Administration

  • Oral
  • Injectable

The route of administration segment for the antiplatelet drugs market is segmented into oral and injectable.

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end-users, the antiplatelet drugs market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the antiplatelet drugs market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Antiplatelet Drugs Market Regional Analysis/Insights

The Antiplatelet drugs market is analysed and market size insights and trends are provided by country, drug, indication, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Antiplatelet drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the antiplatelet drugs market because of the growing adoption of newer technologies and increasing demand for diseases-specific treatment. Additionally, the growing presence of major key players and rising healthcare expenditure will further propel the market's growth rate.

Europe is expected to grow during the forecast period due to the surging number of myocardial infraction cases and rising government initiatives in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Antiplatelet Drugs Market Share Analysis

The Antiplatelet drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to antiplatelet drugs market.

Some of the major players operating in the antiplatelet drugs market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France), Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Bayer AG (Germany)
  • AstraZeneca (UK)
  • Johnson & Johnson Private Limited (US)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Bristol-Myers Squibb Company (US)
  • Merck & Co., Inc. (US)
  • DAIICHI SANKYO COMPANY, LIMITED (Japan)
  • Otsuka America Pharmaceutical, Inc. (US)
  • Eli Lilly and Company (US)
  • AbbVie Inc. (US)
  • Genentech, Inc.
  • Baxter (US)
  • Bausch Health Companies Inc. (Canada) 

Research Methodology: Global Antiplatelet Drugs Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The market value for Antiplatelet Drugs Market in 2021 is USD 2.05 billion.
The Antiplatelet Drugs Market is to grow at a CAGR of 8.10% during the forecast period of 2022 to 2029
The expansion of the Global Antiplatelet Drugs Market will be fueled by the sedentary lifestyle of people and rising incidences of cardiovascular diseases. Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of global antiplatelet drugs market.